GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhongyuan Union Cell & Gene Engineering Corp Ltd (SHSE:600645) » Definitions » Return-on-Tangible-Equity

Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Return-on-Tangible-Equity : 7.04% (As of Sep. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Zhongyuan Union Cell & Gene Engineering Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Zhongyuan Union Cell & Gene Engineering's annualized net income for the quarter that ended in Sep. 2024 was ¥193 Mil. Zhongyuan Union Cell & Gene Engineering's average shareholder tangible equity for the quarter that ended in Sep. 2024 was ¥2,747 Mil. Therefore, Zhongyuan Union Cell & Gene Engineering's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2024 was 7.04%.

The historical rank and industry rank for Zhongyuan Union Cell & Gene Engineering's Return-on-Tangible-Equity or its related term are showing as below:

SHSE:600645' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -5.34   Med: 4.2   Max: 32.97
Current: 3.84

During the past 13 years, Zhongyuan Union Cell & Gene Engineering's highest Return-on-Tangible-Equity was 32.97%. The lowest was -5.34%. And the median was 4.20%.

SHSE:600645's Return-on-Tangible-Equity is ranked better than
82.91% of 1258 companies
in the Biotechnology industry
Industry Median: -46.81 vs SHSE:600645: 3.84

Zhongyuan Union Cell & Gene Engineering Return-on-Tangible-Equity Historical Data

The historical data trend for Zhongyuan Union Cell & Gene Engineering's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhongyuan Union Cell & Gene Engineering Return-on-Tangible-Equity Chart

Zhongyuan Union Cell & Gene Engineering Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.66 -5.34 6.03 4.24 3.84

Zhongyuan Union Cell & Gene Engineering Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.03 -3.66 5.69 6.49 7.04

Competitive Comparison of Zhongyuan Union Cell & Gene Engineering's Return-on-Tangible-Equity

For the Biotechnology subindustry, Zhongyuan Union Cell & Gene Engineering's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhongyuan Union Cell & Gene Engineering's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zhongyuan Union Cell & Gene Engineering's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Zhongyuan Union Cell & Gene Engineering's Return-on-Tangible-Equity falls into.



Zhongyuan Union Cell & Gene Engineering Return-on-Tangible-Equity Calculation

Zhongyuan Union Cell & Gene Engineering's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=106.453/( (2714.96+2834.458 )/ 2 )
=106.453/2774.709
=3.84 %

Zhongyuan Union Cell & Gene Engineering's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=193.312/( (2743.716+2751.219)/ 2 )
=193.312/2747.4675
=7.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Zhongyuan Union Cell & Gene Engineering  (SHSE:600645) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Zhongyuan Union Cell & Gene Engineering Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Zhongyuan Union Cell & Gene Engineering's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhongyuan Union Cell & Gene Engineering Business Description

Traded in Other Exchanges
N/A
Address
45 East of Tianjin Airport Economic Zone nine, Tianjin, CHN, 300304
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
Executives
Li De Fu Director
Wang Xue Jun senior management
Wang Yong Director
Li Hai Bin Director
He Wei senior management
Li Qiang senior management
Wu Ming Yuan Director
Wang Hui Director
Huang Jia Xue senior management
Cao Hai Feng Director
Han Yue E Director
Liu Yong Jun senior management
Cui Jing Xue Supervisors
Yang Guang Xing senior management
Meng Zhi Hong senior management

Zhongyuan Union Cell & Gene Engineering Headlines

No Headlines